NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT02013648 2024-02-23
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)
University of Ulm
Phase 3 Completed
NCT02890784 2023-05-10
DasaHIT
University of Jena
Phase 3 Completed
NCT00549848 2022-08-23
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT01460693 2018-04-24
SPIRIT2
Newcastle University
Phase 3 Completed
NCT00481247 2017-02-15
DASISION
Bristol-Myers Squibb
Phase 3 Completed
NCT00123474 2016-08-25
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00123487 2014-11-03
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00362466 2009-11-20
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Bristol-Myers Squibb
Phase 3 Terminated